Year All2026202520242023202220212020 Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston August 10, 2026 Helus Pharma Appoints Michael Halstead as Chief Executive Officer August 3, 2026 Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026 Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results June 29, 2026 Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering June 25, 2026 Helus Pharma™ Announces US$50 Million Underwritten Offering June 24, 2026 Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress June 24, 2026 Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference June 11, 2026 Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York June 1, 2026 Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference April 30, 2026
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston August 10, 2026
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference June 11, 2026
